摘要
非酒精性脂肪性肝病(NAFLD)已经成为全球流行的慢性肝病,目前还缺乏针对性治疗药物。在“病痰饮者,当以温药和之”中医经典理论指导下,课题组创造性地将苓桂术甘汤用于NAFLD脾阳虚证的治疗,首次发现了苓桂术甘汤通过肝细胞膜甲状腺激素受体途径提高脂肪酸水溶性和增加脂肪酸β氧化的作用新途径,并通过多组学技术手段发现和验证了苓桂术甘汤治疗NAFLD的系统药理学机制。课题组多中心、随机、双盲、安慰剂对照临床试验证实苓桂术甘汤可以改善NAFLD脾阳虚证患者的胰岛素抵抗,首次提供了苓桂术甘汤治疗现代慢病的循证医学证据。苓桂术甘汤被列入国家“十三五”重大新药创制首批经典名方支持项目,已按要求完成各项研究任务,并完成首个经典名方新药注册。上述工作为推动中医传统理论和经典方剂在现代临床慢病防治中的转化应用作出了示范。
Non-alcoholic fatty liver disease(NAFLD)has become a globally prevalent chronic liver disease,and there is still a lack of targeted therapy.Guided by the classical theory of traditional Chinese medicine(TCM)that“those who has phlegm syndrome should be treated with warm medicine”,our research group creatively applied Linggui Zhugan Decoction(LGZG)to the treatment of NAFLD patients with spleen-yang deficiency syndrome,and found that LGZG can improve fatty acid water solubility and increase fatty acidβ-oxidation by working on the the pathway of hepatocyte membrane thyroid hormone receptor.We also discovered and validated the systemic pharmacological mechanism of LGZG in the treatment of NAFLD through multi-omics techniques.Our group confirmed through a multicenter,randomized,double-blind,placebo-controlled clinical trial that LGZG could improve insulin resistance in NAFLD patients with spleen-yang deficiency syndrome,which for the first time provided the evidence-based clinical evidence for the treatment of modern chronic diseases with LGZG.LGZG was included in the first batch of classic formula support projects in the 13th Five-Year Plan of China for the invention of major new drugs.We have completed all the research tasks as required and also the new drug registration of the first classic formula of Linggui Zhugan Decoction.The above-mentioned work is a milestone for promoting the translation and application of traditional Chinese medicine theories and classic formulas in the prevention and treatment of chronic diseases in modern clinics.
作者
柳涛
刘保成
吴涛
党延启
张彤
肖伟
季光
LIU Tao;LIU Baocheng;WU Tao;DANG Yanqi;ZHANG Tong;XIAO Wei;JI Guang(Department of Spleen and Stomach Diseases,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Institute of Spleen and Stomach Diseases,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Shanghai Innovation Center of TCM Health Service,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Institute of Interdisciplinary Integrative Medicine Research,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;School of Pharmacy,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处
《上海中医药杂志》
2022年第5期8-12,7,共6页
Shanghai Journal of Traditional Chinese Medicine
基金
国家自然科学基金国际合作重点项目(81620108030)
关键词
非酒精性脂肪性肝病
代谢相关脂肪性肝病
痰饮病
苓桂术甘汤
经典名方
转化医学
non-alcoholic fatty liver disease
metabolic associated fatty liver disease
phlegm syndrome
Linggui Zhugan Decoction
classic formula
translational medicine
作者简介
柳涛,男,博士,副主任医师,主要从事中医药防治消化系统疾病的临床和基础研究工作;通信作者:季光,主任医师,教授,博士研究生导师,E-mail:jiliver@shutcm.edu.cn,医学博士,二级教授,主任医师,博士生导师,首届岐黄学者,国家百千万人才工程国家级人选,上海市领军人才,人社部“国家有突出贡献中青年专家”称号获得者,2020年入选World's Top 2%Scientists(Elsevier)。现任上海中医药大学党委副书记、上海市炎癌转化病症生物学前沿科学中心首席科学家。兼任中华中医药学会健康管理分会主任委员、脾胃病分会副主任委员。主要从事病证结合原理与方法、代谢性炎症与肿瘤发生研究。担任Global Journal of Digestive Disease、Journal of Integrative Medicine、Integrative Medicine International、BMC Comple mentary Medicine and Therapies等期刊主编或副主编。以第一完成人获教育部和上海市科技进步一等奖3项、二等奖5项,获发明专利授权9项,转化3项
